Hormone Therapy Enhances Anti-PD1 Efficacy in Premenopausal Estrogen Receptor-Positive and HER2-Negative Advanced Breast Cancer

Medicine, Rheumatology and Immunology, Endocrinology, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
hormone therapy   anti-PD1 antibody   estrogen receptor-positive breast cancer   HER2-negative   immune microenvironment   tumor immunotherapy  

Hormone Therapy Enhances Anti-PD-1 Efficacy: A Breakthrough Study Targeting Estrogen Receptor-Positive/HER2-Negative Metastatic Breast Cancer Background: Why Conduct This Study? In recent years, cancer immunotherapies have achieved transformative success, with notable efficacy in “hot tumors,” such as triple-negative breast cancer (TNBC), which hav...

PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer

Medicine, Oncology, Life Sciences, Immunology,
breast cancer   radiation therapy   Pembrolizumab   neoadjuvant chemotherapy   biomarkers   HER2-negative   tumor-infiltrating lymphocytes  

Academic Background Breast cancer is one of the most common cancers among women worldwide, particularly triple-negative breast cancer (TNBC) and hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, which are known for their aggressive nature and poor prognosis. In recent years, immune checkpoint inh...